2004;351:1502?two. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate Oxaliplatin cancer cancer progressing right after docetaxel remedy: a randomised open-label trial. Lancet. 2010;376:1147?four. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies considerably enhance pro-inflammatory cytokines and straight result in bone loss. J Bone Miner Res. 2014; doi: ten.1002/jbmr.2415. This study discovered that myelosuppresive chemotherapies directly result in bone loss. Shandala T, Shen NY, Hopwood B, et al. The part of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?3. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly individuals. Drugs Aging. 2011;28:867?3. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial evaluation. Eur Radiol. 2006;16:619?3. Matsumura S, Jikko A, Hiranuma H, et al. Impact of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?six. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates radiotherapy-induced neighborhood bone loss by improving osteoblast and osteocyte survival. Bone. 2014;67:33?0. Supplies a summary of research in the introduction relating to radiotherapy-induced changes in osteoclast number and activity. Indicates that PTH1-34 may alleviate radiotherapy-induced bone loss by improving osteoblast and osteocyte survival. Manas A, Casas F, Ciria JP, et al. Randomised study of single dose (8 Gy vs. six Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. Clin Transl Oncol. 2008;10:281?. Willey JS, Livingston EW, Robbins ME, et al. Risedronate prevents early radiation-induced osteoporosis in mice at numerous skeletal places. Bone. 2010;46:101?1. Keenawinna L, Oest ME, Mann j.addbeh.2012.10.012 KA, et al. Zoledronic acid prevents loss of trabecular bone just after focal irradiation in mice. Radiat Res. 2013;180:89?9. Longo J, Lutz S, Johnstone C. Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for individuals with osteoblastic bone metastases. Cancer Manag Res. 2013;five:235?2. Roque IF, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011; CD003347. Wissing MD, van Leeuwen FW, van der Pluijm G, et al. Radium223 chloride: extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 2013;19:5822?. Summary of radium-223 in prostate cancer individuals, plus the limitations of at the moment reported clinical research with this novel therapy. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival cdev.12038 in metastatic prostate cancer. N Engl J Med. 2013;369: 213?three. 36. 37.Curr Osteoporos Rep (2015) 13:140?45 Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone. 2011;49:71?.